Affymax, Inc.
Affymax Completes Enrollment in PEARL 2, the Second of Four Phase 3 Clinical Trials of Hematide to Treat Anemia in Chronic Renal Failure Patients
Published in Hospital Business Week, November 23rd, 2008
Affymax, Inc. (Nasdaq:AFFY) announced that enrollment has been completed in the second of four Phase 3 clinical trials of its lead investigational therapy, Hematide(TM), which is being evaluated for the treatment of anemia in chronic renal failure patients. PEARL 2 (Phase 3 Evaluation of Hematide for Anemia Correction in Chronic Renal Failure) is fully enrolled with over 490 non-dialysis patients from over 60 sites in the United States and Europe.
"With PEARL 2 fully enrolled, we have now completed enrollment in our pivotal Phase 3 non-dialysis trials," said Anne-Marie Duliege, M.D., chief medical officer at Affymax. "We are now focusing our attention on finalizing...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Business Week
More Articles from Hospital Business Week
- Abiomed, Inc.
Sutter Medical Center Honored by Abiomed as "Center of Excellence" for Cardiac Care - Advanced Sterilization Products
ASP Launches STERRAD(R) Sterility Guide - Eliminating Paperwork and Ensuring Compliance - Aetna
Aetna Introduces New Chinese-Language Website - Aetna
Aetna Tackles Quality Issues in Genetic Testing for Breast Cancer - Aflac
Aflac Duck Gives Back - AHA Solutions, Inc.
The American Hospital Association Awards its Endorsement to Identity Force's Identity Protection, Compliance and Data Breach Solutions. - More from this issue of Hospital Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
